If there are not enough funds hopefully they are not running the price up just to make an offering.
Must be big news coming
Nathan, it’s an IND. Pre-IND was done long time ago. That said it’s a tedious process to compile all of the documents and requires a lot of QC review. As noted in PR, we rely on many 3rd parties to get it all together.
4:35 PM · Mar 19, 2021 from Los Angeles, CA·Twitter for iPhone
I wish! Have long ways to get back to even
It's been a long time since I checked on this. Is that a good a bad thing?
Can't say I disagree with you at this point.
Pretty sure all this company does anymore is issue their own directors shares. If yinz remember that’s exactly what I said was going to happen with the RS. People argued with me on here saying, “Brady’s shares will be shortened as well”. Ya but they just issue themselves more shares. Oh well... hope they eventually get through clinical on into them. Be honest I don’t even know where they are at at this point.
Yes very true, but it all goes back to who’s going to pay ??, still need insurance to step up!
There will be tons of opioid addicts and alcoholics after this Covid mess!
You’re not getting up-listed. Reverse your reverse split and give those of us who’ve lost $20K+ in value a chance to recoup. This was a good stock when it was in penny land, and clearly the company has no business getting up listed for a few more years, at best...
Do they have any idea when they will bring the compound to market? It seems like they are only surviving because of the grants that bicx has received.
I agree. Looks like Brady answered your question directly with today's update.
Would do a whole lot better if this company could get anything done. Any ideas if and when any clinical trials will begin?
How's everyone doing?
The initial post was about the grant money...nothing else. All the other info you included to indicate "bad news" was already known.
Money is good , what is BAD is that after leading investors to think they were ready to market the implant years ago.
Now they are telling us they haven't even started human trials yet.
Meaning they are years away from a saleable product.
That is not good news at all.
No significant clinical advancement of product no significant raise in share price.
Now how is that good.
Just trying to understand your position and math? If they raised $$ below $15 then how many shares were issued? What substantial amount of royalties have been paid?
what part of my post that you are responding to in which I specifically stated that BICX raised $6 million was wrong, as you claim?
WRONG! BICX raised $6M.
Thanks for the heads- up here...GL
Scam company BICX continues with its FALSE AND MISLEADING statements. This time on the $15.00/share pricing of the $6.0 million private placement. The price was significantly below $15.00/share since a substantial Royalty Agreement also came with the common shares for the $6.0 million
not surprised though
and why is this not surprising?
because this is what scam companies do!
BioCorRx (OTCBB: BICX) is an alcohol treatment and rehabilitation company on the leading edge of alcohol addiction treatment. The company has developed a treatment program that is used by various licensed alcohol addiction clinics throughout the United States.
The program consists of two components:BioCorRx has the worldwide rights (except in Australia and New Zealand) to a highly effective, proprietary implant formulation of the FDA-approved drug, naltrexone. After being surgically implanted by a medical professional, the naltrexone implant significantly reduces cravings for alcohol for as long as a year in some patients, depending on individual metabolism rates.BioCorRx also owns a life coaching program that is tailored specifically to alcoholics. Once a patient has received the implant, they are encouraged to enter the life coaching program to maximize results.
BioCorRx’s revolutionary alcohol treatment program has an 85% success rate as reported by patients in routine telephone and face to face interviews. The implant is administered as an outpatient procedure, and in most cases, patients do not need to miss more than one day of work. They are then able to enter the private life coaching program without co-workers or family members knowing, unless they so choose.
Naltrexone is a medication that blocks the effects of drugs known as opioids and was approved by the FDA in 1995 for the treatment of alcohol dependence.
Naltrexone blocks the parts of the brain that "feel pleasure” when patients use alcohol. When these areas of the brain are blocked, patients feel significantly less cravings for alcohol and even if alcohol is used, the effects of it will be extremely limited - making sobriety the only option. Once medical intervention has reduced the physical need for alcohol, the program goes on to address the patient's psychological needs. The combination of these treatments has resulted in the highest chance of sobriety.
While other companies use naltrexone in their treatments, the drug is typically administered in oral or injection form, requiring their patients to be responsible for taking the medication or scheduling an appointment.
While some patients do well with the oral formulation, there is a drawback that it must be taken daily and a patient whose craving becomes overwhelming can obtain the euphoria simply by skipping a dose before resuming abuse. Patients who received the program developed by BioCorRx are treated with a slow release dose that can last up to year in many patients (depending on various factors such as metabolism rates), which gives the patients a higher success rate for the treatment of alcoholism.
The outpatient naltrexone implant procedure can take as little as 20 minutes under local anesthetic in some cases. Most patients can return to work or their daily routine in the same day, without the cravings for alcohol.
Mission, Vision, Values
BioCorRx is focused on providing leadership and innovation for the treatment of alcoholism by offering a high-quality, comprehensive and cost-effective recovery program that allows patients and their loved ones to celebrate freedom from the cycle of alcohol addiction. Our program is built on a strong foundation of experience and practice, allowing for an improved quality of life for recovering alcoholics.
BioCorRx strives to be the preeminent, long-term alcohol recovery program used by treatment centers around the world for alcoholics, as well as their family and friends. By providing patients a "Fresh Start" on life, they have the opportunity to live happier, healthier, more productive lives away from the damaging impact of alcohol. We have built an organization that is committed to nurturing research for cutting-edge alcohol recovery technologies and integrating those technologies with comprehensive alcohol recovery treatment programs.
BioCorRx provides the opportunity and tools to treatment centers so they can help patients live happier, healthier, and more productive lives to those suffering from alcohol addiction (as well as their family and friends) by helping them break the addiction cycle and live alcohol-free. We want patients to celebrate freedom from the past and hope for the future. Our team consists of physicians, coaches, founders and management that are committed to providing high-quality services and adherence to ethical care.
Our goal is to give our treatment center partners the ability to deliver our program in a timely, warm and compassionate way to give patients, as well as their families and friends, peace of mind. To achieve this, BioCorRx has built its program around highly-qualified alcohol addiction specialists and effective treatment solutions.
We are committed to quality and continuous improvement in order to meet our partners’ needs for an individualized program dedicated to alcohol addiction recovery.
BioCorRx is uniquely poised to gain significant market share of the $22 billion annual alcohol treatment market in the US.
More than 7% of the US population ages 18 years and older or 13.8 million Americans have problems with drinking, including 8.1 million people who suffer from alcoholism. And the costs financially are staggering. Alcohol dependency and abuse costs the US over $220 billion a year. For the sake of comparison, this is greater than the amount of money spent to combat cancer ($196 billion) and obesity ($133 billion).
BioCorRx intends to distribute the program to a new clinic in the United States every 60 to 90 days. Clinics using our program are also holding discussions with major health insurance providers to pay for all or a portion of the treatment fees.
BioCorRx’s research has discovered that demand for its services are high and that growth in highly marketed segments of the population may be achieved through partnering with additional clinic sites. The company is also exploring the sub-licensing of the program to select regions of the US and internationally.
BioCorRx's goal is to meet its growth targets through licensing opportunities by promoting its naltrexone implant product and counseling service model to existing medical clinics and treatment centers that will purchase the program and/or product from the company. In addition, Fresh Start Private intends to open corporately owned clinics in select key markets where it is deemed appropriate.
Stock Price & Charts
BioCorRx is a fully reporting company. Financial reports and other reports are available for view or by visiting the OTCBB.com online website. Audited financial reports are available quarterly.
Company Structure Details
• Kent Emry - CEO, Director
• Brady Granier -COO, Director
• Lourdes Felix -CFO, Director
• Dr. Jorge Andrade, Jr. - Director
• Neil Muller -Co-Founder and President, Director
Locations of independently owned clinics using our Fresh Start Program
Start Fresh Executive Recovery
367 E Virginia Ave
Phoenix, AZ 85004
Fresh Start Private Florida
1415 Panther Lane
Naples, FL 34109
Start Fresh Alcohol Recovery Center
2827 S. 88th St
Omaha NE 68124
Insider Interview Links
December 2, 2013 - thewallstreetanalyzer.com Interview with Brady Granier COO
November 14, 2013 - SmallCapVoice Interview with Kent Emry CEO
October 2, 2013 - SmallCapVoice Interview with Brady Granier COO